Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria

NCT06150924 is registered in ClinicalTrials.gov with Mineralys Therapeutics Inc. as lead sponsor.

NCT NCT06150924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06150924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria
Lead sponsor
Mineralys Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2023
Completion date
April 23, 2025
Enrollment
60 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease